The United States Congress has voted to approve a $425 million increase for Alzheimer’s disease and dementia research funding at the National Institutes of Health (NIH) in 2019.
Learn more about the vote and how additional funding will impact Alzheimer’s.
Both the U.S. House of Representatives and U.S. Senate has passed a $425 million increase for Alzheimer’s research funding at the NIH in 2019, making the total annual budget $2.3 billion for the 2019 fiscal year.
This is the fourth consecutive year that the United States Congress has voted to increase Alzheimer’s funding.
Harry John, CEO and President of the Alzheimer’s Association and Alzheimer’s Impact Movement said the action by the U.S. House and Senate, “reflect the broad, bipartisan commitment to decisively address one of our nation’s highest-impact public health issues through research.”
Furthermore, Alzheimer’s Foundation of America President and CEO, Charles J. Fuschilo Jr., expressed his gratitude for the vote and to government officials for, “recognizing the importance of putting Alzheimer’s front and center and doing so at an unprecedented level.”
He continues, “The National Plan to Address Alzheimer’s Disease calls for a cure or disease-modifying treatment by 2025 and this funding gets us on a viable path toward putting this goal within the realm of possibility. Maintaining the status quo when it comes to Alzheimer’s is not an option.”
This monumental funding increase marks the largest ever funding boost for Alzheimer’s and dementia research, more closely aligning the federal budget with the National Plan to Address Alzheimer’s. What do you think about the funding increase? We’d like to hear your thoughts in the comments below.